Health Economics›Chronic lymphocytic leukemia›Relapsed or refractory non-randomized or retrospective data

Relapsed or refractory non-randomized or retrospective data

Chronic lymphocytic leukemia · 25 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ibrutinib and Ofatumumab Variant #01	—	R 8 431 136	28d	—	—	—	—	—
Lenalidomide and Ofatumumab Variant #01	—	R 2 208 004	28d	—	—	—	—	—
Bendamustine and Ofatumumab Variant #01	—	R 1 183 782	28d	—	—	—	—	—
Alemtuzumab and Rituximab Variant #01	—	R 422 746	28d	—	—	—	—	—
Ibrutinib and Rituximab Variant #05	—	R 391 307	56d	—	—	—	—	3
Ibrutinib, Venetoclax, Obinutuzumab Variant #01	—	R 320 204	28d	—	—	—	—	2
Obinutuzumab monotherapy Variant #03	—	R 166 941	21d	—	—	—	—	—
Venetoclax monotherapy Variant #04	—	R 163 252	28d	—	—	—	—	—
Alemtuzumab monotherapy Variant #01	—	R 132 218	7d	~15.0 mo	—	~66	~R 8 726 355 PFS proxy · indirect	—
Fludarabine and Alemtuzumab Variant #02	—	R 116 300	28d	~23.7 mo	—	~26	~R 3 023 811 PFS proxy · indirect	2
CFAR Variant #01	—	R 107 720	28d	—	—	—	—	—
Fludarabine and Ibrutinib Variant #01	—	R 91 824	28d	—	—	—	—	—
Lenalidomide and Rituximab (R2) Variant #10	—	R 86 746	35d	~39.4 mo	—	~35	~R 3 036 103 PFS proxy · indirect	5
Ruxolitinib monotherapy Variant #01	—	R 60 650	28d	—	—	—	—	2
HDMP-R Variant #03	—	R 54 771	21d	—	—	—	—	—
DFCR Variant #01 Partial	—	R 34 717	28d	—	—	—	—	—
OFAR Variant #01	—	R 31 743	28d	—	—	—	—	—
R-BAC Variant #02	—	R 29 564	28d	—	—	—	—	—
Fludarabine and Prednisone Variant #01	—	R 14 039	28d	—	—	—	—	—
Lenalidomide monotherapy N/A - secondary systemic drug	—	R 6 361	90d	~30.8 mo	—	~11	~R 69 973 PFS proxy · indirect	2
PCR N/A - secondary systemic drug Partial	—	R 172	28d	—	—	—	—	—
Pirtobrutinib monotherapy Variant #01 Partial	—	—	28d	~14.0 mo	—	~16	—	1
Lisocabtagene maraleucel monotherapy Variant #01 Partial	—	—	—	—	—	—	—	—
Idelalisib monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
Zanubrutinib and Obinutuzumab Partial	—	—	—	—	—	—	—	—

25 of 25 regimens shown